Post on 24-Aug-2021
For peer review only
Multiple Chronic Conditions in a Sample of Community-Dwelling Adults with Fibromyalgia in Olmsted County,
Minnesota
Journal: BMJ Open
Manuscript ID: bmjopen-2014-006681
Article Type: Research
Date Submitted by the Author: 19-Sep-2014
Complete List of Authors: Vincent, Ann; Mayo Clinic, Division of General Internal Medicine Whipple, Mary; Mayo Clinic, Division of General Internal Medicine McAllister, Samantha; Mayo Clinic, Division of General Internal Medicine
Aleman, Katherine; Mayo Clinic, Division of General Internal Medicine St Sauver, Jennifer; Mayo Clinic, Department of Health Sciences Research
<b>Primary Subject Heading</b>:
Rheumatology
Secondary Subject Heading: Epidemiology
Keywords: EPIDEMIOLOGY, INTERNAL MEDICINE, Rheumatology < INTERNAL MEDICINE
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open on S
eptember 9, 2021 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2014-006681 on 3 M
arch 2015. Dow
nloaded from
For peer review only
Running Head: MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 1
Multiple Chronic Conditions in a Sample of Community-Dwelling Adults with
Fibromyalgia in Olmsted County, Minnesota
Ann Vincent, MD
Mary O. Whipple, BA, BSN, RN, CCRP
Samantha J. McAllister, BA
Katherine M. Aleman, BA
Jennifer L. St. Sauver, PhD
Affiliations: Division of General Internal Medicine (Dr. Vincent, Ms. Whipple, Ms. McAllister,
and Ms. Aleman), Department of Health Sciences Research (Dr. St. Sauver), Mayo Clinic, 200
First Street SW, Rochester, MN 55902
Correspondence: Ann Vincent, MD; 200 First Street SW, Rochester, MN 55902;
Phone: 507-284-8913; Fax: 507-284-5370; vincent.ann@mayo.edu
Keywords: fibromyalgia, chronic pain, multiple chronic conditions, epidemiology
Word count: 2335
Page 1 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 2
Abstract
Objectives: The objective of this study was to evaluate the problem of multiple chronic
conditions and polypharmacy in patients with fibromyalgia.
Design: Retrospective medical record review.
Setting: Olmsted County, Minnesota.
Participants: 1111 adults with fibromyalgia.
Primary and Secondary Outcome Measures: Number and type of chronic medical and
psychiatric conditions, medication use
Results: Medical record review demonstrated that greater than 50% of the sample had seven or
more chronic conditions. Chronic joint pain/degenerative arthritis was the most frequent
comorbidity (88.7%), followed by depression (75.1%), migraines/chronic headaches (62.4%),
and anxiety (56.5%). Approximately 40% of patients were taking 3 or more medications for
symptoms of fibromyalgia. Sleep aids were the most commonly prescribed medications in our
sample (33.3%) followed by selective serotonin reuptake inhibitors (28.7%), opioids (22.4%)
and serotonin norepinephrine reuptake inhibitors (21.0%).
Conclusions: The results of our study highlight the problem of multiple chronic conditions and
high prevalence of polypharmacy in fibromyalgia. Clinicians who care for patients with
fibromyalgia should take into consideration the presence of multiple chronic conditions when
recommending medications.
Page 2 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 3
Article Summary
Strengths and limitations of this study:
- This is the first study to evaluate the presence of multiple chronic conditions in a large
sample of community-dwelling adults with fibromyalgia.
- Notably, greater than 50% of our sample had seven or more chronic conditions
- Given this was a community-sample in Olmsted County, Minnesota, the results of our
study may not be generalizable to other samples of patients.
- Additionally, we did not include all possible medical and psychiatric conditions in this
study.
- The results of our study highlight the problem of multiple chronic conditions in
fibromyalgia and indicate clinicians who care for patients with fibromyalgia should take
into consideration the presence of multiple chronic conditions.
Page 3 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 4
Page 4 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 5
Introduction
The presence of multiple chronic conditions is increasingly recognized as a challenge in the
medical management of patients with chronic diseases including diabetes, heart disease, obesity,
and arthritis [1, 2]. Although most health care systems are excellent at managing individual
conditions, these systems are often ineffective in caring for patients with multiple chronic
conditions. This is because the care of patients with multiple chronic conditions must
simultaneously consider the interrelationship of different conditions and the implication of
medication choice on the patient’s other conditions. This complicates medical evaluation,
decision-making, and management [3, 4]. For example, the use of steroids to treat polymyalgia
rheumatica in a patient who also has type II diabetes, hypertension, and obesity requires more
complex decision-making than is guided by singular protocols that are currently in use. A
situation such as this is a common observation in clinical practice and is problematic as the
percentage of patients with multiple chronic conditions is steadily increasing [5].
Fibromyalgia is a chronic condition that is relatively common in clinical practice [6, 7] and is
associated with multiple chronic medical and psychiatric conditions. A small body of literature
has reported a high prevalence of headaches, irritable bowel syndrome, chronic fatigue,
rheumatoid arthritis, systemic lupus erythematosus, osteoarthritis, sleep disorders, hypertension,
type II diabetes, depression, and anxiety [8-12] in fibromyalgia, but the majority of these papers
focused on either medical or psychiatric conditions and/or disability. Furthermore, no
publications to date have considered the cumulative burden of multiple chronic conditions in
fibromyalgia. This is important because not only is fibromyalgia difficult to manage, but
fibromyalgia in combination with other chronic medical and psychiatric conditions substantially ,
amplifies a patient’s symptom burden and complicates the medical management for health care
Page 5 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 6
providers. This is further complicated by the use of multiple medications (with multiple side
effects) to manage pain and other symptoms in fibromyalgia, as many of the medications
employed frequently contribute to or exacerbate existing comorbidities [13-15].
Recognizing the presence of multiple chronic conditions and the potential for polypharmacy may
be one step towards improving the current, ineffective management of fibromyalgia. The
objective of this report is to describe the proportion of patients with multiple chronic conditions
and the proportion of patients using multiple medications related to fibromyalgia, in a cohort of
community-dwelling adults with fibromyalgia in Olmsted County, Minnesota.
Materials and Methods
This cross-sectional study utilized a sample of patients identified via the Rochester
Epidemiology Project and previously described [7]. Upon identification of eligible patients,
detailed medical record review was conducted to assess the presence of medical and psychiatric
conditions as outlined below.
The Rochester Epidemiology Project
The Rochester Epidemiology Project (REP) is a unique resource that indexes the medical records
of all residents who receive care in Olmsted County, Minnesota. In Olmsted County, all medical
care is provided by two medical facilities: Mayo Clinic and Olmsted Medical Center. Each
institution uses a unit (or dossier) medical record system, whereby data from an individual (e.g..
demographics, diagnoses, and billing records) are assembled in one place and are made available
for approved research studies under the umbrella of the REP [16, 17]. The majority of residents
receive care at more than one institution, resulting in multiple records to be reviewed for each
person. The REP maintains an index of the diagnostic codes obtained from all of the
Page 6 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 7
participating providers. The REP diagnostic index includes diagnostic codes from the
International Classification of Diseases (HICDA) for conditions identified by physicians during
office visits or hospital stays. This index can be searched to identify groups of patients with a
particular condition of interest in the Olmsted County population. This is a unique resource
captures virtually the entire Olmsted County population [18] and allows for comprehensive
medical record review.
Participants and Procedure
In this study, we utilized the REP to identify patients with fibromyalgia. To do so, we used the
REP diagnostic index to retrieve a list of all Olmsted County residents age 21 years and older
who had received a diagnosis of fibromyalgia (HICDA code 07893-21-3 or ICD-9 code 729.1
(myalgia, myositis, fibromyositis, or fibromyalgia)) between January 1, 2005, and December 31,
2009. Since these codes are not specific to fibromyalgia and include other diagnoses such as
myalgia and myositis, individual medical records of all of the patients retrieved (N=3410) in this
search were reviewed to confirm a diagnosis of fibromyalgia by a health care provider.
Additionally, medical records were reviewed to evaluate the presence of a number of medical
and psychiatric comorbidities most commonly reported in patients with fibromyalgia [8-12].
These included degenerative joint disease/arthritis, rheumatoid arthritis, systemic lupus
erythematosus, plantar fasciitis, migraines/chronic headaches, temporomandibular joint disorder,
chronic pelvic pain, endometriosis, irritable bowel, irritable bladder, anxiety, depression,
dysthymia, bipolar disorder, insomnia, restless legs syndrome, and metabolic syndrome. Given
the retrospective nature of this study and the limited variables available to define metabolic
syndrome, for the purpose of this study, metabolic syndrome was defined as the presence of two
of more of the following: body mass index (BMI) greater than 30, diabetes mellitus type 2,
Page 7 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 8
hypertension, and hyperlipidemia (REFS). Information regarding use of medications related to
fibromyalgia was also abstracted as of the reference date (December 31, 2012). These included
serotonin norepinephrine reuptake inhibitors (SNRI), alpha-2-delta ligands, tricyclic
antidepressants, selective serotonin reuptake inhibitors (SSRI), opioids, tramadol, skeletal
muscle relaxants, benzodiazepines, sleep aids, and other psychiatric medications. Sleep aids
included zolpidem, zaleplon, eszopiclone, trazodone, and melatonin. Other psychiatric
medications included lithium, monamine oxidase inhibitors, antipsychotics, bupropion,
lamotrigine, and tetracyclic antidepressants.
Statistical Analysis
Descriptive statistics were calculated from demographic variables and recorded as means and
standards deviations. The total number of patients with each chronic condition was determined
and reported as percent of the total sample. Similarly, the use of medications in each class as
documented in the medical record was reported as percent of the total sample. In order to
determine the number of patients with multiple conditions, a total number of chronic conditions
was determined for each patient. This process was repeated with medications.
This study was approved by the site’s Institutional Review Board and all participants provided
consent for use of their medical records for research.
Results
A total of 1111 patients had a diagnosis of fibromyalgia confirmed via medical record review.
Patients in this cohort had a mean age of 59.4 (standard deviation 14.2) and a mean BMI of 30.8
(standard deviation 7.7). As expected based on the prevalence of fibromyalgia in the general
population[6, 7], the majority of our sample was female (93.7%). The average duration of
Page 8 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 9
fibromyalgia, based on the date diagnosis first appeared in the medical record, was 11.1 years
(standard deviation 6.0).
Greater than 50% of the sample had seven or more chronic conditions (Fig. 1a). Chronic joint
pain/degenerative arthritis was the most frequent comorbidity (88.7%), followed by depression
(75.1%), migraines/chronic headaches (62.4%), and anxiety (56.5%). Of the sample, 50.5% met
criteria for metabolic syndrome. A list of all medical and psychiatric conditions abstracted are
reported in Table 1.
Table 1 Co-occurring medical conditions and prescription medications among fibromyalgia
patients
Characteristic N (%)
Medical Conditions
Chronic joint pain/Degenerative arthritis 986 [88.7]
Migraines/Chronic Headaches 693 [62.4]
Hyperlipidemia 562 [51.3]
Metabolic Syndrome (per criteria) 539 [50.5]
Obesity (BMI > 30) 519 [48.0]
Hypertension 508 [46.2]
Irritable Bowel 361 [32.5]
Plantar fasciitis 276 [24.8]
Diabetes Mellitus 196 [17.9]
Temporomandibular Joint Disorder 193 [17.4]
Chronic Pelvic Pain 170 [15.3]
Page 9 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 10
Endometriosis (confirmed, females only) 91 [8.7]
Rheumatoid Arthritis 59 [5.3]
Irritable Bladder 44 [4.0]
Systemic Lupus Erythematosus 17 [1.5]
Mental Health Conditions
Depression 834 [75.1]
Anxiety 628 [56.5]
Dysthymia 216 [19.4]
Bipolar Disorder 65 [5.9]
Sleep Conditions
Insomnia 562 [50.6]
Restless Legs Syndrome 225 [20.3]
Medications
Sleep aids 370 [33.3]
SSRI 319 [28.7]
Opioids 249 [22.4]
SNRI 233 [21.0]
Alpha-2-delta ligands 215 [19.4]
Benzodiazepines 214 [19.3]
aOther psychiatric medications 206 [18.5]
Tricyclic antidepressants 190 [17.1]
Tramadol 174 [15.7]
Skeletal muscle relaxants 167 [15.0]
Page 10 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 11
aOther psychiatric medications includes lithium, monamine oxidase inhibitors, antipsychotics,
bupropion, lamotrigine, and tetracyclic antidepressants.
Medication use is also reported in Table 1. Approximately 40% of patients were taking 3 or
more medications for symptoms of fibromyalgia (Fig. 1b). Sleep aids were the most commonly
prescribed medications in our sample (33.3%) followed by SSRIs (28.7%), opioids (22.4%) and
SNRIs (21.0%). Overall, 31.4% of our sample was taking either tramadol or an opioid.
We also evaluated conditions that co-occurred most frequently and medications that were used
most frequently together, as reported in Table 2.
Table 2 Most common combinations of conditions and medications in patients with fibromyalgia
Condition 1 Condition 2 N [%]
Chronic joint pain/Degenerative arthritis Depression 749 [67.4]
Chronic joint pain/Degenerative arthritis Chronic headaches/Migraines 628 [56.5]
Chronic joint pain/Degenerative arthritis Anxiety 569 [51.2]
Depression Anxiety 560 [50.4]
Depression Chronic headaches/Migraines 553 [49.8]
Chronic joint pain/Degenerative arthritis Insomnia 524 [47.2]
Chronic joint pain/Degenerative arthritis Obesity (BMI >30) 467 [43.2]
Chronic joint pain/Degenerative arthritis Hypertension 473 [43.0]
Medication 1 Medication 2
Sleep aids SSRI 130 [11.7]
Page 11 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 12
Sleep aids Opioids 103 [9.3]
Sleep aids aOther psychiatric medications 101 [9.1]
Sleep aids SNRI 97 [8.7]
Sleep aids Alpha-2-delta ligands 92 [8.3]
Opioids SSRI 88 [7.9]
Sleep aids Tramadol 85 [7.7]
Sleep aids Benzodiazepines 80 [7.2]
aOther psychiatric medications includes lithium, monamine oxidase inhibitors, antipsychotics,
bupropion, lamotrigine, and tetracyclic antidepressants.
The conditions that most commonly occurred together were chronic joint pain/degenerative
arthritis and depression (67.4%), followed by chronic joint pain/degenerative arthritis and
migraines/chronic headaches (56.5%), and chronic joint pain/degenerative arthritis and anxiety
(51.2%). The medications that were used most frequently together were sleep aids and SSRI
(11.7%), sleep aids and opioids (9.3%), and sleep aids and other psychiatric medications (9.1%).
Discussion
The results of our study highlight the problem of multiple chronic conditions in fibromyalgia.
Notably, greater than 50% of our sample had seven or more chronic conditions and the most
frequent of those were other pain disorders (chronic joint pain/degenerative arthritis and
migraines/chronic headaches), depression, and anxiety. Given that the presence of unrefreshing
sleep is included in the 2010 fibromyalgia diagnostic criteria [19], it was not surprising that a
high percentage (over 50%) of our sample had a diagnosis of insomnia. While a high prevalence
Page 12 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 13
of obesity in fibromyalgia has been previously reported [20-22] and is present in our sample, we
did not expect to observe so many cases of hypertension, hyperlipidemia, and diabetes mellitus
that resulted in over 50% of our sample meeting criteria for metabolic syndrome. Our results add
to the growing body of evidence regarding the importance of considering the cumulative burden
of multiple chronic conditions in fibromyalgia.
The presence of other pain conditions and anxiety and depressive disorders can contribute to the
overall symptom burden in individual patients with fibromyalgia. Having fibromyalgia, in itself,
is challenging for patients, due to the lack of effective management modalities. When this
problem is exacerbated by the presence of other pain disorders, the burden of pain to a patient
with fibromyalgia is increased. Further complicating this is the high prevalence of depression
and anxiety in fibromyalgia, which can amplify fibromyalgia symptoms and make it difficult to
sort out causal relationships. For example, in order to effectively manage insomnia, it would be
useful to determine whether the insomnia is results from depression or sleep disturbance from
pain. If clinical management of fibromyalgia is to be most effective, evaluations should also take
into consideration the assessment and management of multiple chronic conditions that also
influence a patient’s overall symptom burden.
Another important finding in our study was the high prevalence of the use of multiple
medications in fibromyalgia. Although pain, anxiety, and depression were the most common
chronic conditions, sleep aids were the most commonly prescribed medications in our sample.
This may be reflective of the bidirectional relationship of sleep with pain, anxiety, and
depression. Additionally, greater than 40% of the sample was prescribed three or more
medications for fibromyalgia management, and interestingly, greater than 10% were prescribed 5
or more medications for symptom management. This is concerning in that although these
Page 13 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 14
medications may have therapeutic effects, the side effects of these medications could contribute
to worsening comorbidity. For example, SNRIs that are FDA-approved for fibromyalgia have
both weight gain and increased blood pressure as side effects [13, 15]. Although the use of these
medications to lower pain and improve mood in fibromyalgia may be appropriate, their use could
exacerbate other chronic conditions such as hypertension and obesity. Also, increased weight,
through its physical effects on joints, could worsen chronic joint pain/degenerative arthritis.
Interestingly, a large percentage of patients were using opioids (22.4%), despite the lack of
definitive data supporting their use in fibromyalgia. This indicates the challenge of effectively
managing chronic pain in this population. A large percentage of patients were also using
benzodiazepines (19.3%), although it was unclear whether they were prescribed for anxiety,
sleep, or both. The use sedating medications such as opioids and benzodiazepines in patients
with fibromyalgia with sleep disorders (e.g. sleep disordered breathing) could be problematic.
Therefore, the influence of a multiple medications on a patient’s multiple chronic conditions
should be considered prior to prescribing.
This study was unique in that use of the REP allowed us conduct exhaustive medical record
review in a large sample of community-dwelling adults with fibromyalgia. However, the results
of our study may not be generalizable to other samples of patients with very different
characteristics. Additionally, as we were primarily interested in evaluating the presence of
chronic medical conditions that were commonly observed in the clinical care of patients with
fibromyalgia, we did not include all possible medical and psychiatric conditions in this study.
Despite these potential limitations, this report of multiple chronic conditions and medication use
in a community-dwelling sample of patients with fibromyalgia adds substantially to the
literature.
Page 14 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 15
To conclude, multiple chronic conditions and the use of multiple medications are highly
prevalent in patients with fibromyalgia and pose a unique challenge to the management of this
condition. Clinicians who care for patients with fibromyalgia should take into consideration the
presence of multiple chronic conditions when recommending medications. Furthermore, properly
addressing these multiple chronic conditions may mitigate the patient’s overall illness burden.
Page 15 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 16
Acknowledgements
Study data were collected and managed using REDCap electronic data capture tools hosted at
Mayo Clinic REDCap (Research Electronic Data Capture) is a secure, web-based application
designed to support data capture for research studies, providing 1) an intuitive interface for
validated data entry; 2) audit trails for tracking data manipulation and export procedures; 3)
automated export procedures for seamless data downloads to common statistical packages; and
4) procedures for importing data from external sources.
Page 16 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 17
Funding Statement
This study was made possible using the resources of the Rochester Epidemiology Project, which
is supported by the National Institute on Aging of the National Institutes of Health under Award
Number R01AG034676. The content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institutes of Health.
Page 17 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 18
Contributorship Statement
Conception and design (AV, MOW, JLS); acquisition, analysis or interpretation of data (AV,
MOW, SJM, KMA, JLS); drafting the work or revising it critically for important intellectual
content; final approval of the version to be published (AV, MOW, SJM, KMA, JLS); agreement
to accountable for all aspects of the work in ensuring that questions related to the accuracy or
integrity of any part of the work are appropriately investigated and resolved (AV, MOW, SJM,
KMA, JLS)
Competing Interests
The authors declare they have no conflict of interest.
Data Sharing Statement
There are no additional, unpublished data.
References
1 Grembowski D, Schaefer J, Johnson KE, et al. A conceptual model of the role of complexity in
the care of patients with multiple chronic conditions. Med Care 2014;52(Suppl 3):S7-S14.
2 Leroy L, Bayliss E, Domino M, et al. The Agency for Healthcare Research and Quality
Multiple Chronic Conditions Research Network: overview of research contributions and
future priorities. Med Care 2014; 52(Suppl 3):S15-22.
3 Tinetti ME, Basu J. Research on multiple chronic conditions: Where we are and where we need
to go. Med Care 2014; 52(Suppl 3):S3-6.
4 Wyatt KD, Stuart LM, Brito JP, et al. Out of context: clinical practice guidelines and patients
with multiple chronic conditions: a systematic review. Med Care 2014;52(Suppl 3):S92-
S100.
5 Partnership for Solutions. Chronic conditions: making the case for ongoing care. Johns
Hopkins University 2004.
Page 18 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 19
6 Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the
general population. Arthritis Rheum 1995;38(1):19-28.
7 Vincent A, Lahr BD, Wolfe F, et al. Prevalence of fibromyalgia: A population-based study in
Olmsted County, Minnesota, utilizing the Rochester Epidemiology Project. Arthritis Care
Res 2013;65(5):786-792.
8 Arnold LM, Hudson JI, Keck PE, et al. Comorbidity of fibromyalgia and psychiatric disorders.
J Clin Psychiatry 2006; 67(8):1219-1225.
9 Buskila D, Cohen H. Comorbidity of fibromyalgia and psychiatric disorders. Curr Pain
Headache Rep 2007;11(5):333-338.
10 Przekop P, Haviland MG, Zhao Y, et al. Self-reported physical health, mental health, and
comorbid diseases among women with irritable bowel syndrome, fibromyalgia, or both
compared with healthy control respondents. J Am Osteopath Assoc 2012;112(11):726-735.
11 Weir PT, Harlan GA, Nkoy FL, et al. The incidence of fibromyalgia and its associated
comorbidities: a population-based retrospective cohort study based on International
Classification of Diseases, 9th revision codes. J Clin Rheumatol 2006;12(3):124-128.
12 White LA, Birnbaum HG, Kaltenboeck A, et al. Employees with fibromyalgia: medical
comorbidity, healthcare costs, and work loss. J Occup Environ Med 2008;50(1):13-24.
13 Savella (milnacipran hydrochloride) tablets [prescribing information]. St. Louis, MO: Forest
Pharmaceuticals 2009.
14 Lyrica (pregabalin) capusules [prescribing information]. New York, NY: Pfizer, Inc. 2009.
15 Cymbalta (duloxetine hydrochloride) delayed release capsules [prescribing information].
Indianapolis, IN: Eli Lilly and Company 2008.
Page 19 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 20
16 Rocca WA, Yawn BP, St Sauver JL, et al. History of the Rochester Epidemiology Project:
half a century of medical records linkage in a US population. Mayo Clin Proc
2012;87(12):1202-1213.
17 St Sauver JL, Grossardt BR, Yawn BP, et al. Data resource profile: the Rochester
Epidemiology Project (REP) medical records-linkage system. Int J Epidemiol
2012;41(6):1614-1624.
18 St Sauver JL, Grossardt BR, Yawn BP, et al. Use of a medical records linkage system to
enumerate a dynamic population over time: the Rochester Epidemiology Project. Am J
Epidemiol 2011;173(9):1059-1068.
19 Wolfe F, Clauw DJ, Fitzcharles M-A, et al. Fibromyalgia criteria and severity scales for
clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic
Criteria for Fibromyalgia. J Rheumatol 2011;38(6):1113-1122.
20 Okifuji A, Donaldson GW, Barck L, et al. Relationship between fibromyalgia and obesity in
pain, function, mood, and sleep. J Pain 2010;11(12):1329-1337.
21 Ursini F, Naty S, Grembiale RD. Fibromyalgia and obesity: the hidden link. Rheumatol Int
2011;31(11):1403-1408.
22 Yunus MB, Arslan S, Aldag JC. Relationship between body mass index and fibromyalgia
features. Scand J Rheumatol 2002;31(1):27-31.
Page 20 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 21
Fig. 1 Pie charts demonstrating the proportion of patient with fibromyalgia that have multiple
comorbidities (panel a) and proportion of patients that are taking multiple medications (panel b)
Page 21 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 22
Author Contributions
Conception and design (AV, MOW, JLS); acquisition, analysis or interpretation of data (AV,
MOW, SJM, KMA, JLS); drafting the work or revising it critically for important intellectual
content; final approval of the version to be published (AV, MOW, SJM, KMA, JLS); agreement
to accountable for all aspects of the work in ensuring that questions related to the accuracy or
integrity of any part of the work are appropriately investigated and resolved (AV, MOW, SJM,
KMA, JLS)
Page 22 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
254x93mm (96 x 96 DPI)
Page 23 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of cross-sectional studies
Section/Topic Item
# Recommendation Reported on page #
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract 1
(b) Provide in the abstract an informative and balanced summary of what was done and what was found 2
Introduction
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported 6-7
Objectives 3 State specific objectives, including any prespecified hypotheses 7
Methods
Study design 4 Present key elements of study design early in the paper 7
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data
collection
7-8
Participants
6
(a) Give the eligibility criteria, and the sources and methods of selection of participants 8
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if
applicable
8-9
Data sources/
measurement
8* For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe
comparability of assessment methods if there is more than one group
8-9
Bias 9 Describe any efforts to address potential sources of bias NA since this was a
medical record
review
Study size 10 Explain how the study size was arrived at 8-9
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and
why
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding 9
(b) Describe any methods used to examine subgroups and interactions 9
(c) Explain how missing data were addressed NA
(d) If applicable, describe analytical methods taking account of sampling strategy 7
Page 24 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on September 9, 2021 by guest. Protected by copyright. http://bmjopen.bmj.com/ BMJ Open: first published as 10.1136/bmjopen-2014-006681 on 3 March 2015. Downloaded from
For peer review only
(e) Describe any sensitivity analyses NA
Results
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility,
confirmed eligible, included in the study, completing follow-up, and analysed
8-9
(b) Give reasons for non-participation at each stage NA medical record
review
(c) Consider use of a flow diagram NA
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential
confounders
9
(b) Indicate number of participants with missing data for each variable of interest NA
Outcome data 15* Report numbers of outcome events or summary measures 9-13
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence
interval). Make clear which confounders were adjusted for and why they were included
NA
(b) Report category boundaries when continuous variables were categorized 10
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period NA
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses NA
Discussion
Key results 18 Summarise key results with reference to study objectives 13
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and
magnitude of any potential bias
15
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from
similar studies, and other relevant evidence
15
Generalisability 21 Discuss the generalisability (external validity) of the study results 15
Other information
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on
which the present article is based
4
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.
Page 25 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on September 9, 2021 by guest. Protected by copyright. http://bmjopen.bmj.com/ BMJ Open: first published as 10.1136/bmjopen-2014-006681 on 3 March 2015. Downloaded from
For peer review only
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE
checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.
Page 26 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on September 9, 2021 by guest. Protected by copyright. http://bmjopen.bmj.com/ BMJ Open: first published as 10.1136/bmjopen-2014-006681 on 3 March 2015. Downloaded from
For peer review only
A Cross-Sectional Assessment of the Prevalence of Multiple Chronic Conditions and Medication Use in a Sample of
Community-Dwelling Adults with Fibromyalgia in Olmsted County, Minnesota
Journal: BMJ Open
Manuscript ID: bmjopen-2014-006681.R1
Article Type: Research
Date Submitted by the Author: 02-Jan-2015
Complete List of Authors: Vincent, Ann; Mayo Clinic, Division of General Internal Medicine Whipple, Mary; Mayo Clinic, Division of General Internal Medicine McAllister, Samantha; Mayo Clinic, Division of General Internal Medicine Aleman, Katherine; Mayo Clinic, Division of General Internal Medicine St Sauver, Jennifer; Mayo Clinic, Department of Health Sciences Research
<b>Primary Subject Heading</b>:
Rheumatology
Secondary Subject Heading: Epidemiology
Keywords: EPIDEMIOLOGY, INTERNAL MEDICINE, Rheumatology < INTERNAL MEDICINE
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open on S
eptember 9, 2021 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2014-006681 on 3 M
arch 2015. Dow
nloaded from
For peer review only
Running Head: MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 1
A Cross-Sectional Assessment of the Prevalence of Multiple Chronic Conditions and
Medication Use in a Sample of Community-Dwelling Adults with Fibromyalgia in Olmsted
County, Minnesota
Ann Vincent, MD
Mary O. Whipple, BA, BSN, RN, CCRP
Samantha J. McAllister, BA
Katherine M. Aleman, BA
Jennifer L. St. Sauver, PhD
Affiliations: Division of General Internal Medicine (Dr. Vincent, Ms. Whipple, Ms. McAllister,
and Ms. Aleman), Department of Health Sciences Research (Dr. St. Sauver), Mayo Clinic, 200
First Street SW, Rochester, MN 55902
Correspondence: Ann Vincent, MD; 200 First Street SW, Rochester, MN 55902;
Phone: 507-284-8913; Fax: 507-284-5370; vincent.ann@mayo.edu
Keywords: fibromyalgia, chronic pain, multiple chronic conditions, epidemiology
Page 1 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 2
Word count: 24355
Abstract
Objectives: The objective of this study was to evaluate the problem of multiple chronic
conditions and polypharmacy in patients with fibromyalgia.
Design: Retrospective medical record review.
Setting: Olmsted County, Minnesota.
Participants: 1111 adults with fibromyalgia.
Primary and Secondary Outcome Measures: Number and type of chronic medical and
psychiatric conditions, medication use
Results: Medical record review demonstrated that greater than 50% of the sample had seven or
more chronic conditions. Chronic joint pain/degenerative arthritis was the most frequent
comorbidity (88.7%), followed by depression (75.1%), migraines/chronic headaches (62.4%),
and anxiety (56.5%). Approximately 40% of patients were taking 3 or more medications for
symptoms of fibromyalgia. Sleep aids were the most commonly prescribed medications in our
sample (33.3%) followed by selective serotonin reuptake inhibitors (28.7%), opioids (22.4%)
and serotonin norepinephrine reuptake inhibitors (21.0%).
Conclusions: The results of our study highlight the problem of multiple chronic conditions and
high prevalence of polypharmacy in fibromyalgia. Clinicians who care for patients with
fibromyalgia should take into consideration the presence of multiple chronic conditions when
recommending medications.
Page 2 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 3
Article Summary
Strengths and limitations of this study:
- This is the first study to evaluate the presence of multiple chronic conditions in a large
sample of community-dwelling adults with fibromyalgia.
- Notably, greater than 50% of our sample had seven or more chronic conditions
- Given this was a community-sample in Olmsted County, Minnesota, the results of our
study may not be generalizable to other samples of patients.
- Additionally, we did not include all possible medical and psychiatric conditions in this
study.
- The results of our study highlight the problem of multiple chronic conditions in
fibromyalgia and indicate clinicians who care for patients with fibromyalgia should take
into consideration the presence of multiple chronic conditions.
Page 3 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 4
Funding Statement
This study was made possible using the resources of the Rochester Epidemiology Project, which
is supported by the National Institute on Aging of the National Institutes of Health under Award
Number R01AG034676. The content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institutes of Health.
Page 4 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 5
Competing Interests
The authors declare they have no conflict of interest.
Page 5 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 6
Introduction
The presence of multiple chronic conditions is increasingly recognized as a challenge in the
medical management of patients with chronic diseases including diabetes, heart disease, obesity,
and arthritis [1, 2]. Although most health care systems are excellent at managing individual
conditions, these systems are often ineffective in caring for patients with multiple chronic
conditions. This is because the care of patients with multiple chronic conditions must
simultaneously consider the interrelationship of different conditions and the implication of
medication choice on the patient’s other conditions. This complicates medical evaluation,
decision-making, and management [3, 4]. For example, the use of steroids to treat polymyalgia
rheumatica in a patient who also has type II diabetes, hypertension, and obesity requires more
complex decision-making than is guided by singular protocols that are currently in use. A
situation such as this is a common observation in clinical practice and is problematic as the
percentage of patients with multiple chronic conditions is steadily increasing [5].
Fibromyalgia is a chronic condition that is relatively common in clinical practice [6, 7] and is
associated with multiple chronic medical and psychiatric conditions. A small body of literature
has reported a high prevalence of headaches, irritable bowel syndrome, chronic fatigue,
rheumatoid arthritis, systemic lupus erythematosus, osteoarthritis, sleep disorders, hypertension,
type II diabetes, depression, and anxiety [8-12] in fibromyalgia, but the majority of these papers
focused on either medical or psychiatric conditions and/or disability. Furthermore, no
publications to date have considered the cumulative burden of multiple chronic conditions in
fibromyalgia. This is important because not only is fibromyalgia difficult to manage, but
fibromyalgia in combination with other chronic medical and psychiatric conditions substantially ,
amplifies a patient’s symptom burden and complicates the medical management for health care
Page 6 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 7
providers. This is further complicated by the use of multiple medications (with multiple side
effects) to manage pain and other symptoms in fibromyalgia, as many of the medications
employed frequently contribute to or exacerbate existing comorbidities [13-15].
Recognizing the presence of multiple chronic conditions and the potential for polypharmacy may
be one step towards improving the current, ineffective management of fibromyalgia. The
objective of this report is to describe the proportion of patients with multiple chronic conditions
and the proportion of patients using multiple medications related to fibromyalgia, in a cohort of
community-dwelling adults with fibromyalgia in Olmsted County, Minnesota.
Materials and Methods
This cross-sectional study utilized a sample of patients identified via the Rochester
Epidemiology Project and previously described [7]. Upon identification of eligible patients,
detailed medical record review was conducted to assess the presence of medical and psychiatric
conditions as outlined below.
The Rochester Epidemiology Project
The Rochester Epidemiology Project (REP) is a unique resource that indexes the medical records
of all residents who receive care in Olmsted County, Minnesota. In Olmsted County, all medical
care is provided by two medical facilities: Mayo Clinic and Olmsted Medical Center. Each
institution uses a unit (or dossier) medical record system, whereby data from an individual (e.g..
demographics, diagnoses, and billing records) are assembled in one place and are made available
for approved research studies under the umbrella of the REP [16, 17]. The majority of residents
receive care at more than one institution, resulting in multiple records to be reviewed for each
person. The REP maintains an index of the diagnostic codes obtained from all of the
Page 7 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 8
participating providers. The REP diagnostic index includes diagnostic codes from the
International Classification of Diseases (HICDA) for conditions identified by physicians during
office visits or hospital stays. This index can be searched to identify groups of patients with a
particular condition of interest in the Olmsted County population. This is a unique resource
captures virtually the entire Olmsted County population [18] and allows for comprehensive
medical record review.
Participants and Procedure
In this study, we utilized the REP to identify patients with fibromyalgia. To do so, we used the
REP diagnostic index to retrieve a list of all Olmsted County residents age 21 years and older
who had received a diagnosis of fibromyalgia (HICDA code 07893-21-3 or ICD-9 code 729.1
(myalgia, myositis, fibromyositis, or fibromyalgia)) between January 1, 2005, and December 31,
2009. Since these codes are not specific to fibromyalgia and include other diagnoses such as
myalgia and myositis, individual medical records of all of the patients retrieved in this search
were reviewed to confirm a diagnosis of fibromyalgia by a health care provider. Of the 3410
patients identified, 86 declined authorization for medical record review. Medical records were
reviewed to evaluate the presence of a number of medical and psychiatric comorbidities most
commonly reported in patients with fibromyalgia [8-12]. These included degenerative joint
disease/arthritis, rheumatoid arthritis, systemic lupus erythematosus, plantar fasciitis,
migraines/chronic headaches, temporomandibular joint disorder, chronic pelvic pain,
endometriosis, irritable bowel, irritable bladder, anxiety, depression, dysthymia, bipolar disorder,
insomnia, restless legs syndrome, and metabolic syndrome. Given the retrospective nature of this
study and the limited variables available to define metabolic syndrome, for the purpose of this
study, metabolic syndrome was defined as the presence of two of more of the following: body
Page 8 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 9
mass index (BMI) greater than 30, diabetes mellitus type 2, hypertension, and hyperlipidemia
(REFS). Information regarding use of medications related to fibromyalgia was also abstracted as
of the reference date (December 31, 2012). These included serotonin norepinephrine reuptake
inhibitors (SNRI), alpha-2-delta ligands, tricyclic antidepressants, selective serotonin reuptake
inhibitors (SSRI), opioids, tramadol, skeletal muscle relaxants, benzodiazepines, sleep aids, and
other psychiatric medications. Sleep aids included zolpidem, zaleplon, eszopiclone, trazodone,
and melatonin. Other psychiatric medications included lithium, monamine oxidase inhibitors,
antipsychotics, bupropion, lamotrigine, and tetracyclic antidepressants.
Statistical Analysis
Descriptive statistics were calculated from demographic variables and recorded as means and
standards deviations. The total number of patients with each chronic condition was determined
and reported as percent of the total sample. Similarly, the use of medications in each class as
documented in the medical record was reported as percent of the total sample. In order to
determine the number of patients with multiple conditions, a total number of chronic conditions
was determined for each patient. This process was repeated with medications.
This study was approved by the site’s Institutional Review Board and all participants provided
consent for use of their medical records for research.
Results
A total of 1111 patients had a diagnosis of fibromyalgia confirmed via medical record review.
Patients in this cohort had a mean age of 59.4 (standard deviation 14.2) and a mean BMI of 30.8
(standard deviation 7.7). As expected based on the prevalence of fibromyalgia in the general
population[6, 7], the majority of our sample was female (93.7%). The average duration of
Page 9 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 10
fibromyalgia, based on the date diagnosis first appeared in the medical record, was 11.1 years
(standard deviation 6.0).
Greater than 50% of the sample had seven or more chronic conditions (Fig. 1a). Chronic joint
pain/degenerative arthritis was the most frequent comorbidity (88.7%), followed by depression
(75.1%), migraines/chronic headaches (62.4%), and anxiety (56.5%). Of the sample, 50.5% met
criteria for metabolic syndrome. A list of all medical and psychiatric conditions abstracted are
reported in Table 1.
Table 1 Co-occurring medical conditions and prescription medications among fibromyalgia
patients
Characteristic N (%)
Medical Conditions
Chronic joint pain/Degenerative arthritis 986 [88.7]
Migraines/Chronic Headaches 693 [62.4]
Hyperlipidemia 562 [51.3]
Obesity (BMI > 30) 519 [48.0]
Hypertension 508 [46.2]
Irritable Bowel 361 [32.5]
Plantar fasciitis 276 [24.8]
Diabetes Mellitus, type II 196 [17.9]
Temporomandibular Joint Disorder 193 [17.4]
Chronic Pelvic Pain 170 [15.3]
Endometriosis (confirmed, females only) 91 [8.2]
Page 10 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 11
Rheumatoid Arthritis 59 [5.3]
Irritable Bladder 44 [4.0]
Systemic Lupus Erythematosus 17 [1.5]
Mental Health Conditions
Depression 834 [75.1]
Anxiety 628 [56.5]
Dysthymia 216 [19.4]
Bipolar Disorder 65 [5.9]
Sleep Conditions
Insomnia 562 [50.6]
Restless Legs Syndrome 225 [20.3]
Medications
Sleep aids 370 [33.3]
SSRI 319 [28.7]
Opioids 249 [22.4]
SNRI 233 [21.0]
Alpha-2-delta ligands 215 [19.4]
Benzodiazepines 214 [19.3]
aOther psychiatric medications 206 [18.5]
Tricyclic antidepressants 190 [17.1]
Tramadol 174 [15.7]
Skeletal muscle relaxants 167 [15.0]
Page 11 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 12
aOther psychiatric medications includes lithium, monamine oxidase inhibitors, antipsychotics,
bupropion, lamotrigine, and tetracyclic antidepressants.
Medication use is also reported in Table 1. Approximately 40% of patients were taking 3 or
more medications for symptoms of fibromyalgia (Fig. 1b). Sleep aids were the most commonly
prescribed medications in our sample (33.3%) followed by SSRIs (28.7%), opioids (22.4%) and
SNRIs (21.0%). Overall, 31.4% of our sample was taking either tramadol or an opioid.
We also evaluated conditions that co-occurred most frequently and medications that were used
most frequently together, as reported in Table 2.
Table 2 Most common combinations of conditions and medications in patients with fibromyalgia
Condition 1 Condition 2 N [%]
Chronic joint pain/Degenerative arthritis Depression 749 [67.4]
Chronic joint pain/Degenerative arthritis Chronic headaches/Migraines 628 [56.5]
Chronic joint pain/Degenerative arthritis Anxiety 569 [51.2]
Depression Anxiety 560 [50.4]
Depression Chronic headaches/Migraines 553 [49.8]
Chronic joint pain/Degenerative arthritis Insomnia 524 [47.2]
Chronic joint pain/Degenerative arthritis Obesity (BMI >30) 467 [43.2]
Chronic joint pain/Degenerative arthritis Hypertension 473 [43.0]
Medication 1 Medication 2
Sleep aids SSRI 130 [11.7]
Sleep aids Opioids 103 [9.3]
Page 12 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 13
Sleep aids aOther psychiatric medications 101 [9.1]
Sleep aids SNRI 97 [8.7]
Sleep aids Alpha-2-delta ligands 92 [8.3]
Opioids SSRI 88 [7.9]
Sleep aids Tramadol 85 [7.7]
Sleep aids Benzodiazepines 80 [7.2]
aOther psychiatric medications includes lithium, monamine oxidase inhibitors, antipsychotics,
bupropion, lamotrigine, and tetracyclic antidepressants.
The conditions that most commonly occurred together were chronic joint pain/degenerative
arthritis and depression (67.4%), followed by chronic joint pain/degenerative arthritis and
migraines/chronic headaches (56.5%), and chronic joint pain/degenerative arthritis and anxiety
(51.2%). The medications that were used most frequently together were sleep aids and SSRI
(11.7%), sleep aids and opioids (9.3%), and sleep aids and other psychiatric medications (9.1%).
Discussion
The results of our study highlight the problem of multiple chronic conditions in fibromyalgia.
Notably, greater than 50% of our sample had seven or more chronic conditions and the most
frequent of those were other pain disorders (chronic joint pain/degenerative arthritis and
migraines/chronic headaches), depression, and anxiety. Given that the presence of unrefreshing
sleep is included in the 2010 fibromyalgia diagnostic criteria [19], it was not surprising that a
high percentage (over 50%) of our sample had a diagnosis of insomnia. While a high prevalence
of obesity in fibromyalgia has been previously reported [20-22] and is present in our sample, we
Page 13 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 14
did not expect to observe so many cases of hypertension, hyperlipidemia, and diabetes mellitus
that resulted in over 50% of our sample meeting criteria for metabolic syndrome. Our results add
to the growing body of evidence regarding the importance of considering the cumulative burden
of multiple chronic conditions in fibromyalgia.
The presence of other pain conditions and anxiety and depressive disorders can contribute to the
overall symptom burden in individual patients with fibromyalgia. Having fibromyalgia, in itself,
is challenging for patients, due to the lack of effective management modalities. When this
problem is exacerbated by the presence of other pain disorders, the burden of pain to a patient
with fibromyalgia is increased. Further complicating this is the high prevalence of depression
and anxiety in fibromyalgia, which can amplify fibromyalgia symptoms and make it difficult to
sort out causal relationships. For example, in order to effectively manage insomnia, it would be
useful to determine whether the insomnia is results from depression or sleep disturbance from
pain. If clinical management of fibromyalgia is to be most effective, evaluations should also take
into consideration the assessment and management of multiple chronic conditions that also
influence a patient’s overall symptom burden.
Another important finding in our study was the high prevalence of the use of multiple
medications in fibromyalgia. Although pain, anxiety, and depression were the most common
chronic conditions, sleep aids were the most commonly prescribed medications in our sample.
This may be reflective of the bidirectional relationship of sleep with pain, anxiety, and
depression. Additionally, greater than 40% of the sample was prescribed three or more
medications for fibromyalgia management, and interestingly, greater than 10% were prescribed 5
or more medications for symptom management. This is concerning in that although these
medications may have therapeutic effects, the side effects of these medications could contribute
Page 14 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 15
to worsening comorbidity. For example, SNRIs that are FDA-approved for fibromyalgia have
both weight gain and increased blood pressure as side effects [13, 15]. Although the use of these
medications to lower pain and improve mood in fibromyalgia may be appropriate, their use could
exacerbate other chronic conditions such as hypertension and obesity. Also, increased weight,
through its physical effects on joints, could worsen chronic joint pain/degenerative arthritis.
Interestingly, a large percentage of patients were using opioids (22.4%), despite the lack of
definitive data supporting their use in fibromyalgia. This indicates the challenge of effectively
managing chronic pain in this population. A large percentage of patients were also using
benzodiazepines (19.3%), although it was unclear whether they were prescribed for anxiety,
sleep, or both. The use sedating medications such as opioids and benzodiazepines in patients
with fibromyalgia with sleep disorders (e.g. sleep disordered breathing) could be problematic.
Therefore, the influence of a multiple medications on a patient’s multiple chronic conditions
should be considered prior to prescribing.
A recent paper by Rocca et al. provides estimates of the prevalence of five of the chronic
conditions also assessed in our study in general population of Olmsted County [23]. Among
those age 50-69 years in the general population, the prevalence of arthritis, hyperlipidemia,
hypertension, diabetes, and depression was 13.2-22.2%, 33.2-50.6%, 23.8-42.9%, 15.9-26.6%,
and 12.0-14.5%, respectively. Except for diabetes, these conditions appear to be more common
in our sample of patients with fibromyalgia.
This study was unique in that use of the REP allowed us conduct exhaustive medical record
review in a large sample of community-dwelling adults with fibromyalgia. However, the results
of our study may not be generalizable to other samples of patients with very different
characteristics. Additionally, as we were primarily interested in evaluating the presence of
Page 15 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 16
chronic medical conditions that were commonly observed in the clinical care of patients with
fibromyalgia, we did not include all possible medical and psychiatric conditions in this study.
Another limitation is that as 86 of the 3410 patients originally identified did not provide
authorization for researchers to use their medical records, and therefore could not be included in
the medical record review, which is a potential source of bias. Despite these potential limitations,
this report of multiple chronic conditions and medication use in a community-dwelling sample of
patients with fibromyalgia adds substantially to the literature.
To conclude, multiple chronic conditions and the use of multiple medications are highly
prevalent in patients with fibromyalgia and pose a unique challenge to the management of this
condition. Clinicians who care for patients with fibromyalgia should take into consideration the
presence of multiple chronic conditions when recommending medications. Furthermore, properly
addressing these multiple chronic conditions may mitigate the patient’s overall illness burden.
Page 16 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 17
Acknowledgements
Study data were collected and managed using REDCap electronic data capture tools hosted at
Mayo Clinic REDCap (Research Electronic Data Capture) is a secure, web-based application
designed to support data capture for research studies, providing 1) an intuitive interface for
validated data entry; 2) audit trails for tracking data manipulation and export procedures; 3)
automated export procedures for seamless data downloads to common statistical packages; and
4) procedures for importing data from external sources.
Page 17 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 18
References
1 Grembowski D, Schaefer J, Johnson KE, et al. A conceptual model of the role of complexity in
the care of patients with multiple chronic conditions. Med Care 2014;52(Suppl 3):S7-S14.
2 Leroy L, Bayliss E, Domino M, et al. The Agency for Healthcare Research and Quality
Multiple Chronic Conditions Research Network: overview of research contributions and
future priorities. Med Care 2014; 52(Suppl 3):S15-22.
3 Tinetti ME, Basu J. Research on multiple chronic conditions: Where we are and where we need
to go. Med Care 2014; 52(Suppl 3):S3-6.
4 Wyatt KD, Stuart LM, Brito JP, et al. Out of context: clinical practice guidelines and patients
with multiple chronic conditions: a systematic review. Med Care 2014;52(Suppl 3):S92-
S100.
5 Partnership for Solutions. Chronic conditions: making the case for ongoing care. Johns
Hopkins University 2004.
6 Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the
general population. Arthritis Rheum 1995;38(1):19-28.
7 Vincent A, Lahr BD, Wolfe F, et al. Prevalence of fibromyalgia: A population-based study in
Olmsted County, Minnesota, utilizing the Rochester Epidemiology Project. Arthritis Care
Res 2013;65(5):786-792.
8 Arnold LM, Hudson JI, Keck PE, et al. Comorbidity of fibromyalgia and psychiatric disorders.
J Clin Psychiatry 2006; 67(8):1219-1225.
9 Buskila D, Cohen H. Comorbidity of fibromyalgia and psychiatric disorders. Curr Pain
Headache Rep 2007;11(5):333-338.
Page 18 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 19
10 Przekop P, Haviland MG, Zhao Y, et al. Self-reported physical health, mental health, and
comorbid diseases among women with irritable bowel syndrome, fibromyalgia, or both
compared with healthy control respondents. J Am Osteopath Assoc 2012;112(11):726-735.
11 Weir PT, Harlan GA, Nkoy FL, et al. The incidence of fibromyalgia and its associated
comorbidities: a population-based retrospective cohort study based on International
Classification of Diseases, 9th revision codes. J Clin Rheumatol 2006;12(3):124-128.
12 White LA, Birnbaum HG, Kaltenboeck A, et al. Employees with fibromyalgia: medical
comorbidity, healthcare costs, and work loss. J Occup Environ Med 2008;50(1):13-24.
13 Savella (milnacipran hydrochloride) tablets [prescribing information]. St. Louis, MO: Forest
Pharmaceuticals 2009.
14 Lyrica (pregabalin) capusules [prescribing information]. New York, NY: Pfizer, Inc. 2009.
15 Cymbalta (duloxetine hydrochloride) delayed release capsules [prescribing information].
Indianapolis, IN: Eli Lilly and Company 2008.
16 Rocca WA, Yawn BP, St Sauver JL, et al. History of the Rochester Epidemiology Project:
half a century of medical records linkage in a US population. Mayo Clin Proc
2012;87(12):1202-1213.
17 St Sauver JL, Grossardt BR, Yawn BP, et al. Data resource profile: the Rochester
Epidemiology Project (REP) medical records-linkage system. Int J Epidemiol
2012;41(6):1614-1624.
18 St Sauver JL, Grossardt BR, Yawn BP, et al. Use of a medical records linkage system to
enumerate a dynamic population over time: the Rochester Epidemiology Project. Am J
Epidemiol 2011;173(9):1059-1068.
Page 19 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 20
19 Wolfe F, Clauw DJ, Fitzcharles M-A, et al. Fibromyalgia criteria and severity scales for
clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic
Criteria for Fibromyalgia. J Rheumatol 2011;38(6):1113-1122.
20 Okifuji A, Donaldson GW, Barck L, et al. Relationship between fibromyalgia and obesity in
pain, function, mood, and sleep. J Pain 2010;11(12):1329-1337.
21 Ursini F, Naty S, Grembiale RD. Fibromyalgia and obesity: the hidden link. Rheumatol Int
2011;31(11):1403-1408.
22 Yunus MB, Arslan S, Aldag JC. Relationship between body mass index and fibromyalgia
features. Scand J Rheumatol 2002;31(1):27-31.
23 Rocca WA, Boyd CM, Grossardt, BR, et al. Prevalence of multimorbidity in a geographically
defined American population: patterns by age, sex, and race/ethnicity. Mayo Clin
Proc;89(10):1336-1349.
Page 20 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 21
Fig. 1 Pie charts demonstrating the percentage of patients with fibromyalgia who have multiple
comorbidities (panel a) and the percentage of patients who are taking multiple medications
(panel b)
Page 21 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
MULTIPLE CHRONIC CONDITIONS IN FIBROMYALGIA 22
Author Contributions
Conception and design (AV, MOW, JLS); acquisition, analysis or interpretation of data (AV,
MOW, SJM, KMA, JLS); drafting the work or revising it critically for important intellectual
content; final approval of the version to be published (AV, MOW, SJM, KMA, JLS); agreement
to accountable for all aspects of the work in ensuring that questions related to the accuracy or
integrity of any part of the work are appropriately investigated and resolved (AV, MOW, SJM,
KMA, JLS)
Page 22 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
254x90mm (300 x 300 DPI)
Page 23 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on Septem
ber 9, 2021 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2014-006681 on 3 March 2015. D
ownloaded from
For peer review only
STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of cross-sectional studies
Section/Topic Item
# Recommendation Reported on page #
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract 1
(b) Provide in the abstract an informative and balanced summary of what was done and what was found 2
Introduction
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported 6-7
Objectives 3 State specific objectives, including any prespecified hypotheses 7
Methods
Study design 4 Present key elements of study design early in the paper 7
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data
collection
7-8
Participants
6
(a) Give the eligibility criteria, and the sources and methods of selection of participants 8
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if
applicable
8-9
Data sources/
measurement
8* For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe
comparability of assessment methods if there is more than one group
8-9
Bias 9 Describe any efforts to address potential sources of bias NA since this was a
medical record
review15
Study size 10 Explain how the study size was arrived at 8-9
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and
why
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding 9
(b) Describe any methods used to examine subgroups and interactions 9
(c) Explain how missing data were addressed NA
(d) If applicable, describe analytical methods taking account of sampling strategy 7
Page 24 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on September 9, 2021 by guest. Protected by copyright. http://bmjopen.bmj.com/ BMJ Open: first published as 10.1136/bmjopen-2014-006681 on 3 March 2015. Downloaded from
For peer review only
(e) Describe any sensitivity analyses NA
Results
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility,
confirmed eligible, included in the study, completing follow-up, and analysed
8-9
(b) Give reasons for non-participation at each stage NA medical record
review8
(c) Consider use of a flow diagram NA
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential
confounders
9
(b) Indicate number of participants with missing data for each variable of interest NA
Outcome data 15* Report numbers of outcome events or summary measures 9-13
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence
interval). Make clear which confounders were adjusted for and why they were included
NA
(b) Report category boundaries when continuous variables were categorized 10
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period NA
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses NA
Discussion
Key results 18 Summarise key results with reference to study objectives 13
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and
magnitude of any potential bias
15
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from
similar studies, and other relevant evidence
15
Generalisability 21 Discuss the generalisability (external validity) of the study results 15
Other information
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on
which the present article is based
4
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.
Page 25 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on September 9, 2021 by guest. Protected by copyright. http://bmjopen.bmj.com/ BMJ Open: first published as 10.1136/bmjopen-2014-006681 on 3 March 2015. Downloaded from
For peer review only
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE
checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.
Page 26 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on September 9, 2021 by guest. Protected by copyright. http://bmjopen.bmj.com/ BMJ Open: first published as 10.1136/bmjopen-2014-006681 on 3 March 2015. Downloaded from